Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06979570 · ClinicalTrials.gov registry record · NA

Personalized Performance Optimization Platform

A NA study of Neurocognitive Function and Sensory Science, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
2
Study locations

NCT06979570: Recruiting NA study of Neurocognitive Function and Sensory Science, sponsored by Massachusetts General Hospital.

NCT06979570 is a NA study of Neurocognitive Function and Sensory Science that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 303-participant average among 3 other Neurocognitive Function trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06979570, a NA study of Neurocognitive Function and Sensory Science, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
2
Study locations

Study Summary

Crews of future long-duration exploration missions will have to cope with a wide range of stressors that present significant challenges for maintaining optimal performance. Crews will have to operate under conditions of high workload, reduced sleep and circadian dysregulation, limited sensory stimulation, confinement and extended separation from family and friends, and communication delays isolating them from real-time interaction with ground support, which may be particularly critical in the event of emergencies. These factors present significant risks to optimal cognitive/behavioral functioning and performance, across individuals and teams, and such challenges will only increase in criticality as human exploration moves beyond Earth's orbit to targets such as the Moon and Mars. To help mitigate these risks, Massachusetts General Hospital, along with collaborators at the Massachusetts Institute of Technology, will investigate a novel, personalized and scalable, closed-loop platform technology for on-board behavioral health management-one which adapts the local working environment to optimize performance based on biosensor feedback.

Primary Outcome

A cognitive assessment designed to measure working memory speed and accuracy. During the task, participants are presented with a sequence of stimuli (letters, numbers, or spatial locations) and must indicate whether the current stimulus matches the one presented earlier. Performance is assessed through reaction time, accuracy, and response variability, providing insight into both cognitive processing speed and working memory capacity.

Interventions

  • DEVICE AttentivU

Study Locations (2)

Massachusetts

  • MIT Media Lab - Cambridge
  • Massachusetts General Hospital - Charlestown

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2021-02-22
Est. Completion 2025-12-30
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT06979570 shows while recruiting

NCT06979570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 303-participant average among 3 other Neurocognitive Function trials with a reported enrollment target (74% lower).

The record links to 5 conditions, with Neurocognitive Function appearing as the primary indexed condition, and to 1 intervention - of which AttentivU is the first listed.

NCT06979570 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06979570 about?

NCT06979570 is a clinical study titled "Personalized Performance Optimization Platform". Crews of future long-duration exploration missions will have to cope with a wide range of stressors that present significant challenges for maintaining optimal performance. Crews will have to operate under conditions of high workload, reduced sleep and circadian dysregulation, limited sensory stimul...

What is the current status of trial NCT06979570?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2021-02-22. Estimated completion is 2025-12-30.

What conditions does trial NCT06979570 study?

This clinical trial studies the following conditions: Neurocognitive Function, Sensory Science, Performance Assessment, Countermeasure Evaluation, Psychological Factors.

What interventions are being tested in trial NCT06979570?

The interventions under investigation include: AttentivU (DEVICE).

Who is sponsoring clinical trial NCT06979570?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06979570 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurocognitive Function

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06979570, the US trial registry maintained by the National Library of Medicine. NCT06979570 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.